5980 HORTON STREET, EMERYVILLE, CA
Announces Pricing of $100 Million Public Offering of Common Stock
Investor Presentation
Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
Earnings Release
Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Changes in Board, Management or Compensation
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Free Writing Prospectus
SEC Staff Correspondence
Correspondence
Submission Upload
Deregistration Letter